| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 29, 2023 |
| Accession Number: | 0001437749-23-018514 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2021 | $4.00 → $3.50 | Neutral | Goldman Sachs |
| 8/6/2021 | $5.00 → $4.50 | Neutral | Goldman Sachs |
15-12G - Quotient Ltd (0001596946) (Filer)
EFFECT - Quotient Ltd (0001596946) (Filer)
EFFECT - Quotient Ltd (0001596946) (Filer)
SC 13D - Quotient Ltd (0001596946) (Subject)
SC 13D/A - Quotient Ltd (0001596946) (Subject)
SC 13D/A - Quotient Ltd (0001596946) (Subject)
Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously
Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously
Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00
Gainers Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering. Palisade Bio, Inc. (NASDAQ:PALI) shares jumped 80.1% to $5.80. Palisade Bio announced $2.5 million registered direct offering and concurrent private placement priced above market under Nasdaq rules. Silo Pharma, Inc. (NASDAQ:SILO) gained 63.7% to $5.60 after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis progression. F-star Therapeutics, Inc. (NASDAQ:FSTX) shares gained 42.8% to $5.84. F-Star Th
Gainers Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering. Evaxion Biotech A/S (NASDAQ:EVAX) rose 34.4% to $2.38 in pre-market trading. Evaxion Biotech said on Dec 22, the FDA notified the company that it had reviewed the company's IND for Phase 2b clinical trial of EVX-01 in combination with Keytruda. Sesen Bio, Inc. (NASDAQ:SESN) shares rose 30.4% to $0.6590 in pre-market trading after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per share, in connect
Gainers Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ:QTNT) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ:BXRX) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ:PALI) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction i
Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno
JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.
JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé
MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica
JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot
Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022 MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne
JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effect no earlier than ten days after the date of that Form 25 filing. The Company expects that as a result of this voluntary delisting, the last trading day of its ordinary shares on the Nasda
JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP
JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when the market opens on November 3, 2022 on the Nasdaq under the existing symbol "QTNT." The Reverse Stock Split is primarily intended to bring the Company into compliance
3 - Quotient Ltd (0001596946) (Issuer)
3 - Quotient Ltd (0001596946) (Issuer)
4 - Quotient Ltd (0001596946) (Issuer)